High-throughput sequencing technology, including whole-exome sequencing (WES), has revolutionized gene discovery in epilepsy. It has also demonstrated the significant genetic heterogeneity of epilepsy and the importance of de novo mutations in the epileptic encephalopathies,^[@R1]^ which are the most severe forms of epilepsy. Recently, WES in a family quintet with 2 affected siblings with early-onset epileptic encephalopathy (EOEE) and cerebellar atrophy identified fibroblast growth factor 12 (*FGF12*, also known as *FHF1*) as a putative gene responsible.^[@R2]^ A de novo gain-of-function variant (p.R52H) was found in 2 affected siblings with lethal disease. *FGF12* encodes a cytosolic protein that interacts with neuronal sodium channels and increases their voltage-dependent fast inactivation.^[@R3]^ Here, we performed WES-trio analysis and identified the same de novo missense mutation in 2 patients with severe neonatal-onset epilepsy and variable clinical outcomes.

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

This study was approved by site-specific Institutional Review Boards, and informed consent was obtained from all individuals.

Genetic analysis. {#s1-2}
-----------------

Peripheral blood samples were collected from the proband and her parents. Genomic DNA was extracted from peripheral blood lymphocytes following standard protocols. Patient 1 exonic regions were captured using the Ion AmpliSeq Exome Kit (57.7 Mb), and WES was performed on the Ion Proton System according to manufacturers\' recommendations (Life Technologies, Carlsbad, CA). Candidate variants were validated by Sanger sequencing as previously described.^[@R4]^ Primer sequences and PCR conditions are available on request. Patient 2 was identified through GeneMatcher ([genematcher.org/](http://genematcher.org/)).^[@R5]^ WES and data analysis were performed as part of a trio-based clinical sequencing study at HudsonAlpha. Exome capture was completed using Nimblegen SeqCap EZ Exome v3 (Roche, Basel, Switzerland), and sequencing was conducted on the Illumina HiSeq 2000 (Illumina, San Diego, CA). Sanger confirmation of variants, including confirmation of absence from both biological parents, was performed by a College of American Pathologists/Clinical Laboratory Improvement Amendments--certified or Diagnostic Accreditation Program--accredited diagnostic laboratory.

RESULTS {#s2}
=======

Family trio analysis identified the same *FGF12* missense mutation in both patients, identical to the variant reported previously.^[@R2]^ The mutation is a de novo heterozygous G\>A transition at position 155 of the complementary DNA (NM_004113) which results in a p.R52H missense substitution. Sanger sequencing was performed in both trios and confirmed that the mutation was only present in the affected probands. No other pathogenic mutations in known epilepsy genes were present.

Clinical phenotypes. {#s2-1}
--------------------

Patient 1 is a developmentally normal 11-month-old baby, born at term after an uncomplicated pregnancy. She presented on day 3 of life with a 2-minute seizure involving extension of all limbs, head, and eye deviation to the right side and apnea with desaturation. On day 3, the interictal EEG showed multifocal spikes. During continuous video-EEG monitoring on day 8, multiple independent left and right frontal seizures were recorded. Seizures occurred from sleep, and 1 typical seizure with corresponding EEG is shown in the video at [Neurology.org/ng](10.1212/NXG.0000000000000120) and in the [figure](#F1){ref-type="fig"}. Seizures continued despite treatment with phenobarbital, levetiracetam, topiramate, and a midazolam infusion. She required intubation and ventilation for 3 days. Her seizures stopped on day 20 of age after the addition of phenytoin. She had 1--3 seizures per month on phenytoin and topiramate. Carbamazepine was added to topiramate at 6 weeks of age, and she has been seizure free since 5 months of age on carbamazepine (30 mg/kg/d). Her initial neurologic examination showed mild hypotonia which later resolved. Her development remains normal. Her head circumference remains at the 85th percentile, and her EEG performed at 10 months of age was normal. Extensive neurometabolic investigations and a head MRI performed at day 4 of life were unremarkable.

![Patient 1: Ictal EEG\
Seizure began with arousal from sleep and extension of all 4 limbs followed by clonic jerking of the right arm and bradycardia (see video). Ictal EEG demonstrated (A) generalized attenuation of EEG activity at seizure onset, followed by rhythmic spikes in left central area; (B) spread to right central area; (C) spread to bilateral central frontal parietal regions; and (D) postictal suppression.](NG2016003046FF1){#F1}

Patient 2 is a 15-year-old girl, born at term following an uncomplicated pregnancy and delivery. She presented on day 2 of life with tonic seizures characterized by generalized stiffening which evolved to intermittent stiffening and twitching of the limbs. On day 11, her EEG demonstrated suppression of the background and multifocal spikes. Seizures did not respond to phenobarbital, clonazepam, topiramate, and lamotrigine. At 4 years of age, she developed focal seizures with impaired awareness which could evolve to bilateral tonic-clonic seizures. The interictal EEG showed mild background slowing and left frontotemporal spikes. Carbamazepine was tried at 4 years of age; however, it was stopped immediately following an allergic reaction. Rufinamide was added to lamotrigine at the age of 8 years and at most recent follow-up, the patient has been seizure free for 1 year. Developmental delay was noted by 1 year of age, and her development regressed at times of increased seizure frequency. She currently has moderate intellectual disability and autism. MRI of the brain at 2 weeks and 2 years of age was normal except for an incidental Chiari I malformation.

DISCUSSION {#s3}
==========

In this report, we describe 2 additional patients with a de novo p.R52H mutation in *FGF12* but with milder phenotypes. The same variant observed in our patients was recently described in 2 siblings with a lethal disorder characterized by EOEE and cerebellar atrophy.^[@R2]^ All 4 affected individuals presented with early-onset tonic seizures and most had seizures from sleep ([table](#T1){ref-type="table"}). Patient 1 does not have an epileptic encephalopathy given the cessation of seizures, normal development, and normal EEG. However, patient 2 and the original reported clinical features of the siblings^[@R2]^ are consistent with an epileptic encephalopathy. In all cases, seizures were refractory to multiple antiseizure medications. However, patient 1 had a good response to sodium channel blockers and has been seizure free since 5 months of age. In patient 2, carbamazepine resulted in an allergic reaction and phenytoin was not tried. Patient 2 is currently seizure free on a combination of lamotrigine and rufinamide, which is possibly due to the effects of these drugs on the sodium channel. The current neurologic examination and development are normal for patient 1. This contrasts with the report of the siblings, which indicates a neurodegenerative course associated with early death. The clinical course of patient 2 also is not as severe as that of the siblings; however, her seizures were refractory to treatment except for the past year, and she did have developmental regression associated with increased seizure activity. She also has intellectual disability and autism. In the original report,^[@R2]^ progressive cerebellar atrophy was also a prominent feature of the disease phenotype which differs from the normal MRI seen in patient 1 and the incidental Chiari I malformation identified on MRI in patient 2. It is difficult to accurately compare MRI findings given the young age of patient 1; however, MRI of patient 2 showed no sign of cerebellar atrophy at age 2. The milder phenotype with normal clinical outcome seen in patient 1 may be influenced by the early seizure control. However, other genetic and/or environmental factors may also be playing a role. Although the young age of patient 1 limits a clear impression of the natural history of this disorder, there is a striking clinical difference between patient 1 normal clinical course to date and moderate to severe course of patient 2 and the lethal outcome of the previously described siblings. Early seizure control in patient 1 suggests possible important treatment implications for this genetic disorder which could affect outcome.

###### 

Clinical features of patients with de novo p.R52H *FGF12* mutation

![](NG2016003046TT1)

During the preparation of this manuscript, we became aware of 3 additional patients with an epileptic encephalopathy carrying the same *FGF12* de novo mutation.^[@R6]^ The identification of a recurrent de novo mutation in 6 unrelated patients all presenting with early-onset epilepsy strongly supports the involvement of *FGF12* in disease pathogenesis.^[@R7],[@R8]^ Moreover, the identification of additional patients carrying the same *FGF12* variant broadens the phenotypic spectrum associated with this gene.
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